BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

728.3M

Vuru Grade

21.00/100

Current Price

$10.14
-0.145 (-1.41%)

Stability Price

$0.19
Overvalued by 98.16%

Company Metrics

  • 0 P/E
  • 54.29 P/S
  • 8.85 P/B
  • -0.677 EPS
  • -118.77% Cash ROIC
  • 2.49 Cash Ratio
  • 0 / 0% Dividend
  • 881,345.00 Avg. Vol.
  • 55.22M Shares
  • 728.3M Market Cap.

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Insider Transaction Update: BioCryst Pharmaceuticals, Inc. Director Buys ...
Ashburn Daily - 5 hours ago
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the Director of Biocryst Pharmaceuticals Inc, Hutson Nancy J, had purchased 10,000 shares in a ...
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) in Spotlight
Markets Wired - Feb 25, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced financial results for the fourth quarter and full year ended December 31, 2014.
Revenue Update on BioCryst Pharmaceuticals, Inc. - Ashburn Daily
Price Target Update on BioCryst Pharmaceuticals, Inc. - Bar and Graph Report
UPDATE: BioCryst Pharmaceuticals Posts Narrower-Than-Expected Q4 Loss
Benzinga - Feb 18, 2015
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) reported a narrower-than-expected loss for the fourth quarter. The Durham, North Carolina-based company posted a quarterly loss of $11.7 million, or $0.16 per share, versus a year-ago net loss of $5.4 ...
BioCryst Pharmaceuticals, Inc. Analyst Rating Update - Stafford Daily
BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results - CNNMoney
Earnings Peek: BioCryst Pharmaceuticals Likely To Beat Estimates (BCRX)
Seeking Alpha (registration) - Jan 27, 2015
BioCryst Pharmaceuticals (NASDAQ:BCRX) is a small biotechnology company with a market cap of $814 million. It develops novel small molecule drugs that block key enzymes involved in orphan and infectious diseases.
BioCryst Pharma (BCRX) Granted Orphan Drug and Fast Track Status from the ... - Wall Street Pit
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary ... - MarketWatch
BioCryst Pharmaceuticals Inc. (BCRX) is Trading Higher on Unusual Volume for ...
Equities.com - Feb 24, 2015
BioCryst Pharmaceuticals Inc. ($BCRX) experienced unusually high volume on Feb. 23, as the stock gained 3.55% to a closing price of $10.51.
Company Shares of BioCryst Pharmaceuticals, Inc. Rally 0.9% - Ashburn Daily
BioCryst Pharmaceuticals Shares Up 6.6% Following Insider Buying Activity ... - Dakota Financial News
Zacks Long Term Rating Update on BioCryst Pharmaceuticals, Inc.
Wall Street Pulse - Feb 24, 2015
As much as 9 analysts have advised buy on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) with an average broker rating of 1.56.
BioCryst Pharmaceuticals Inc. (BCRX) is Trading Lower on Unusual Volume for ...
Equities.com - Feb 23, 2015
BioCryst Pharmaceuticals Inc. ($BCRX) experienced unusually high volume on Feb. 23, as the stock gained 3.55% to a closing price of $10.51.
BioCryst Pharmaceuticals, Inc. Registers High Short Percent of Float
Stafford Daily - Feb 3, 2015
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) are valued at $9.98 per share. The price is 31.7% off the 52-week high and 27% above the 52-week low.
Stock Insight: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Markets Wired - Jan 29, 2015
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of ...
Shares of BioCryst Pharmaceuticals, Inc. Sinks by -7.37% for the Week
Ashburn Daily - Feb 2, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has lost 7.37% during the past week and dropped 16.15% in the past 4 weeks.
Zacks Rating Disclosure on BioCryst Pharmaceuticals, Inc. - Rock Hill Daily